Generics in the Netherlands

December 2024 | 38 pages | ID: GCCD7E3E699EN
MarketLine

Abstracts

Generics in the Netherlands

Summary

Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value 2018-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

• A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
• The Dutch generics market recorded revenues of $1.2 billion in 2023, representing a compound annual growth rate (CAGR) of 2.9% between 2018 and 2023.
• Market consumption volume increased with a CAGR of 0.4% between 2018 and 2023, to reach a total of 80.2 % of total pharma volume in 2023.
• According to GlobalData, in 2023, the Dutch generics market grew by 3.2% annually. The growth is attributed to the country’s mounting aging population. According to the United States Census Bureau, in 2023, the population aged 65 years and above in the Netherlands reached 3.7 million, up 3.4% over 2022.

Scope

• Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in the Netherlands
• Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the Netherlands
• Leading company profiles reveal details of key generics market players’ global operations and financial performance
• Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands generics market with five year forecasts

Reasons to Buy

• What was the size of the Netherlands generics market by value in 2023?
• What will be the size of the Netherlands generics market in 2028?
• What factors are affecting the strength of competition in the Netherlands generics market?
• How has the market performed over the last five years?
• What are the main segments that make up the Netherlands's generics market?

Contents

1 EXECUTIVE SUMMARY

1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive landscape

2 MARKET OVERVIEW

2.1. Market definition
2.2. Market analysis

3 MARKET DATA

3.1. Market value
3.2. Market volume

4 MARKET SEGMENTATION

4.1. Geography segmentation

5 MARKET OUTLOOK

5.1. Market value forecast
5.2. Market volume forecast

6 FIVE FORCES ANALYSIS

6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry

7 COMPETITIVE LANDSCAPE

7.1. Who are the leading players?
7.2. What are the strengths of the leading player?
7.3. Have there been any recent developments in the market?

8 COMPANY PROFILES

8.1. Sandoz Group AG
8.2. Teva Pharmaceutical Industries Ltd
8.3. Viatris Inc
8.4. Sanofi

9 MACROECONOMIC INDICATORS

9.1. Country data

10 APPENDIX

10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine